Free tool
FAERS Monitor: Ztalmy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215904 or its brand name (Ztalmy, Ganaxolone). Reports on generic versions are filed under their own applications.
Reports
670
Serious
350
52% of reports
Hospitalization
112
Death reported
16
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure204
- product dose omission issue101
- drug ineffective88
- somnolence58
- change in seizure presentation43
- pneumonia31
- off label use28
- vomiting24
- fatigue15
- illness15
- weight decreased15
- pyrexia12
- urinary tract infection11
- death10
- weight increased10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 24 |
| 2023 | 109 |
| 2024 | 197 |
| 2025 | 279 |
| 2026 | 59 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,489 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| change in seizure presentationSignal | 43 | 2237.1 | 1657.4 | 87,648 |
| seizureSignal | 204 | 55.5 | 49.5 | 10,912 |
| product dose omission issueSignal | 101 | 10.8 | 9.0 | 899 |
| somnolenceSignal | 58 | 9.0 | 7.1 | 411 |
| illnessSignal | 15 | 4.6 | 2.8 | 39 |
| pneumoniaSignal | 31 | 3.0 | 2.1 | 40 |
| drug ineffectiveSignal | 88 | 2.1 | 1.7 | 53 |
| urinary tract infectionSignal | 11 | 2.0 | 1.1 | 5 |
| weight decreased | 15 | 1.7 | 1.0 | 4 |
| vomiting | 24 | 1.6 | 1.1 | 5 |
| weight increased | 10 | 1.4 | 0.8 | 1 |
| pyrexia | 12 | 1.1 | 0.6 | 0 |
| off label use | 28 | 1.0 | 0.7 | 0 |
| fatigue | 15 | 0.6 | 0.4 | 4 |
| death | 10 | 0.4 | 0.2 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.